Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels

Completed · Phase 3

Conditions studied: Brain Fibrillarab Levels

In brief

To determine the level of association between quantitative regional estimates of brain uptake of \[18F\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.

Key facts

Study ID

NCT01165554

Run by

GE Healthcare

People needed

203

Starts

2010-05-01

Expected to finish

2011-11-01

Last updated by the study team

2013-12-04

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject has a short life expectancy (approximately 1 year or less) as estimated by the Investigator.
• The subject is 70 years of age or older if cognitively normal, or 55 years of age or older if terminal because of dementia.
• The subject's general health is adequate to undergo the study procedures.

You may not qualify if…

• The subject has a contraindication for PET.
• The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol or to any of the excipients.
• The subject is unable to tolerate or cooperate with study procedures.

Where it is running

• GE Healthcare — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.